Your browser doesn't support javascript.
loading
Contribution of skin cancer to overall healthcare costs of lung transplantation in Queensland, Australia.
Gordon, Louisa G; Hopkins, Peter M; Chambers, Daniel C; Green, Adele C.
Afiliación
  • Gordon LG; QIMR Berghofer Medical Research Institute, Population Health Department, Brisbane, Queensland, Australia; Queensland University of Technology, School of Nursing, Institute of Health and Biomedical Innovation, Brisbane, Queensland, Australia; The University of Queensland, School of Medicine, Brisbane
  • Hopkins PM; The University of Queensland, School of Medicine, Brisbane, Queensland, Australia; Queensland Lung Transplant Service, Prince Charles Hospital, Queensland Health, Queensland Government, Brisbane, Queensland, Australia.
  • Chambers DC; The University of Queensland, School of Medicine, Brisbane, Queensland, Australia; Queensland Lung Transplant Service, Prince Charles Hospital, Queensland Health, Queensland Government, Brisbane, Queensland, Australia.
  • Green AC; QIMR Berghofer Medical Research Institute, Population Health Department, Brisbane, Queensland, Australia; CRUK Manchester Institute and Faculty of Biology Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
J Heart Lung Transplant ; 42(10): 1437-1444, 2023 10.
Article en En | MEDLINE | ID: mdl-37244434
BACKGROUND: Skin cancers are a major source of morbidity in lung transplant recipients, but the relative costs associated with their treatment are unknown. METHODS: We prospectively followed 90 lung transplant recipients from enrollment in the Skin Tumors in Allograft Recipients study in 2013-2015, until mid-2016. We undertook a cost analysis to quantify the health system costs relating to the index transplant episode and ongoing costs for 4 years. Linked data from surveys, Australian Medicare claims, and hospital accounting systems were used, and generalized linear models were employed. RESULTS: Median initial hospitalization costs of lung transplantation were AU$115,831 (interquartile range (IQR) $87,428-$177,395). In total, 57 of 90 (63%) participants were treated for skin cancers during follow-up at a total cost of AU$44,038. Among these 57, total government costs per person (mostly of pharmaceuticals) over 4 years were median AU$68,489 (IQR $44,682-$113,055) vs AU$59,088 (IQR $38,190-$94,906) among those without skin cancer, with the difference predominantly driven by more doctors' visits, and higher pathology and procedural costs. Healthcare costs overall were also significantly higher in those treated for skin cancers (cost ratio 1.50, 95%CI: 1.09, 2.06) after adjusting for underlying lung disease, age on enrollment, years of immunosuppression, and the number of treated comorbidities. CONCLUSIONS: Skin cancer care is a small component of overall costs. While all lung transplant recipients with comorbidities have substantial healthcare costs, those affected by skin cancer incur even greater healthcare costs than those without, highlighting the importance of skin cancer control.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Trasplante de Pulmón Tipo de estudio: Health_economic_evaluation Límite: Aged / Humans País/Región como asunto: Oceania Idioma: En Revista: J Heart Lung Transplant Asunto de la revista: CARDIOLOGIA / TRANSPLANTE Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Trasplante de Pulmón Tipo de estudio: Health_economic_evaluation Límite: Aged / Humans País/Región como asunto: Oceania Idioma: En Revista: J Heart Lung Transplant Asunto de la revista: CARDIOLOGIA / TRANSPLANTE Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos